<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21988742</article-id><article-id pub-id-type="pmc">3198691</article-id><article-id pub-id-type="publisher-id">1745-6215-12-223</article-id><article-id pub-id-type="doi">10.1186/1745-6215-12-223</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>The effect of C1-esterase inhibitor on systemic inflammation in trauma patients with a femur fracture - The CAESAR study: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Heeres</surname><given-names>Marjolein</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>M.Heeres-2@umcutrecht.nl</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Visser</surname><given-names>Tjaakje</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>T.Visser@umcutrecht.nl</email></contrib><contrib contrib-type="author" id="A3"><name><surname>van Wessem</surname><given-names>Karlijn JP</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>K.J.P.Wessem@umcutrecht.nl</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Koenderman</surname><given-names>Anky HL</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>a.koenderman@sanquin.nl</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Strengers</surname><given-names>Paul FW</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>p.strengers@sanquin.nl</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A6"><name><surname>Koenderman</surname><given-names>Leo</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>L.Koenderman@umcutrecht.nl</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A7"><name><surname>Leenen</surname><given-names>Luke PH</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>L.P.H.Leenen@umcutrecht.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Trauma Surgery, University Medical Centre Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands</aff><aff id="I2"><label>2</label>Sanquin Blood Supply Foundation, Plesmanlaan 125, 1066 CX, Amsterdam, The Netherlands</aff><aff id="I3"><label>3</label>Department of Respiratory Medicine, University Medical Centre Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands</aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>11</day><month>10</month><year>2011</year></pub-date><volume>12</volume><fpage>223</fpage><lpage>223</lpage><history><date date-type="received"><day>25</day><month>7</month><year>2011</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2011 Heeres et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Heeres et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.trialsjournal.com/content/12/1/223"/><abstract><sec><title>Background</title><p>Systemic inflammation in response to a femur fracture and the additional fixation is associated with inflammatory complications, such as acute respiratory distress syndrome and multiple organ dysfunction syndrome. The injury itself, but also the additional procedure of femoral fixation induces a release of pro-inflammatory cytokines such as interleukin-6. This results in an aggravation of the initial systemic inflammatory response, and can cause an increased risk for the development of inflammatory complications. Recent studies have shown that administration of the serum protein C1-esterase inhibitor can significantly reduce the release of circulating pro-inflammatory cytokines in response to acute systemic inflammation.</p></sec><sec><title>Objective</title><p>Attenuation of the surgery-induced additional systemic inflammatory response by perioperative treatment with C1-esterase inhibitor of trauma patients with a femur fracture.</p></sec><sec><title>Methods</title><p>The study is designed as a double-blind randomized placebo-controlled trial. Trauma patients with a femur fracture, Injury Severity Score &#x02265; 18 and age 18-80 years are included after obtaining informed consent. They are randomized for administration of 200 U/kg C1-esterase inhibitor intravenously or placebo (saline 0.9%) just before the start of the procedure of femoral fixation. The primary endpoint of the study is &#x00394; interleukin-6, measured at t = 0, just before start of the femur fixation surgery and administration of C1-esterase inhibitor, and t = 6, 6 hours after administration of C1-esterase inhibitor and the femur fixation.</p></sec><sec><title>Conclusion</title><p>This study intents to identify C1-esterase inhibitor as a safe and potent anti-inflammatory agent, that is capable of suppressing systemic inflammation in trauma patients. This might facilitate early total care procedures by lowering the risk of inflammation in response to the surgical intervention. This could result in increased functional outcomes and reduced health care related costs.</p></sec><sec><title>Trial registration</title><p>clinicaltrials.gov <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT01275976">NCT01275976</ext-link> (January 12th 2011)</p></sec></abstract><kwd-group><kwd>ARDS</kwd><kwd>C1-esterase inhibitor</kwd><kwd>Complication</kwd><kwd>Femur</kwd><kwd>Fracture</kwd><kwd>Inflammation</kwd><kwd>Interleukin-6</kwd><kwd>Intramedullary fixation</kwd><kwd>MODS</kwd><kwd>Trauma</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Trauma is a major cause of morbidity and mortality in people under the age of 50 years in the western world [<xref ref-type="bibr" rid="B1">1</xref>]. Death can occur as a direct result of the trauma induced injury, or as result of a dysfunctional immune response [<xref ref-type="bibr" rid="B2">2</xref>]. This excessive immune reaction is caused by the response to tissue injury, such as seen after trauma, surgery or burns. An overwhelming innate immune response is considered to be a major risk factor in the development of post-traumatic organ failure and sepsis. Additional injury, induced by surgical intervention, can increase the overall immune inflammatory reaction [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>The lung is most often the first organ to be affected by an exaggerated systemic immune response, which can result in an acute respiratory distress syndrome (ARDS). This functional impairment can be followed by other organs, such as the liver, gastrointestinal tract and kidneys, leading to the so-called multiple organ dysfunction syndrome (MODS). Presence of ARDS and MODS is a major risk factor for mortality, long time morbidity, a prolonged hospital stay and high health care costs [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>One of the early and systemically released cytokines in the early inflammatory response, is the pro-inflammatory cytokine interleukin-6 (IL-6). Therefore, this cytokine is widely used as an indicator for severity of the systemic inflammatory response in clinical studies [<xref ref-type="bibr" rid="B5">5</xref>]. Serum IL-6 levels have been demonstrated to be closely related to the magnitude of the injury (burden of trauma/first hit) and to the operative procedure (second hit) [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. There is a correlation between the IL-6 concentration and the underlying injury severity. Patients with a Injury Severity Score (ISS) &#x0003e; 18 showed a more pronounced rise of IL-6 concentration compared to patients with a lower injury severity [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Femur fractures, have been found associated with a profound systemic inflammatory response [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. Ideally, fractures should be managed without a clinically important delay to prevent excess blood loss, and preserve function. However, in case of femur fractures, internal fixation increases systemic inflammation [<xref ref-type="bibr" rid="B12">12</xref>]. In trauma patients with an already activated inflammatory response, this increase greatly enhances the risk of an excessive immune response [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. To address this problem, the concept of damage control orthopedics (DCO) was developed [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. This concept aims at minimizing the surgically induced inflammatory response through limiting surgical procedures [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. However, DCO is a controversial approach, because limiting surgical procedures, can lead to a reduced quality of fracture healing, multiple interventions and a prolonged hospital stay. This places the treating surgeon with a difficult dilemma: early total care versus damage control [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Therefore, there is an unmet need for limiting/preventing the surgical induced inflammation, other than limiting or delaying surgery. Until now, there is a lack of pharmacological interventions that can reduce this surgery induced inflammation.</p><p>A promising intervention to attenuate the systemic innate immune response is the treatment with a high concentration of C1-esterase inhibitor (C1-INH) [<xref ref-type="bibr" rid="B21">21</xref>]. C1-INH is an acute phase protein, produced by the liver in response to inflammatory conditions. C1-INH is a major inhibitor for both the complement and the contact system, and is, therefore, an important regulator of inflammatory reactions [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. Apart from the modulation of the these systems, C1-INH has also been shown to attenuate systemic inflammation independently of the activation of complement [<xref ref-type="bibr" rid="B24">24</xref>]. In fact, Dorresteijn et al showed that administration of C1-INH, in a 'human endotoxemia model', attenuates the release of pro-inflammatory cytokines, including IL-6, in healthy male volunteers [<xref ref-type="bibr" rid="B21">21</xref>]. This model evokes a systemic inflammatory response in the absence of complement activation [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B25">25</xref>].</p><sec><title>Aim of the study</title><p>The aim of this study is to ascertain whether administration of C1-INH in trauma patients with a femur fracture can reduce the release of pro-inflammatory cytokines and, therefore, will contribute to attenuation of the inflammatory response, in response to a surgical intervention (second hit). This study can provide proof of principle for C1-INH as a potential drug for the prevention of late inflammatory complications in trauma patients.</p></sec></sec><sec sec-type="methods"><title>Methods</title><sec><title>Objectives</title><p>Attenuation of the surgery-induced additional systemic inflammatory response by perioperative treatment with C1-INH in trauma patients with a femur fracture. And the effect of C1-INH on clinical outcome (e.g. ARDS, MODS, mortality, length of hospital stay).</p></sec><sec><title>Study design</title><p>This clinical trial is a double blind, placebo-controlled, randomized study, investigating the anti-inflammatory effect of C1-INH on systemic inflammation induced by fixation of the femur fracture in trauma patients.</p><p>This study is conducted in accordance with the principles of the Declaration of Helsinki [<xref ref-type="bibr" rid="B26">26</xref>] and Good Clinical Practice Guidelines [<xref ref-type="bibr" rid="B27">27</xref>]. The independent ethics committee of the University Medical Centre Utrecht (UMCU) approved the study. Written informed consent will be obtained from all participating patients.</p></sec><sec><title>Study population</title><p>Seventy multi-trauma patients presented at the emergency department of the UMCU with an ISS &#x02265; 18 and a femur fracture which need fixation, will be included in the study. Patients are eligible for the study if they meet all the inclusion and none of the exclusion criteria (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Patients in- and exclusion criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>Inclusion criteria</italic></th><th align="left"><italic>Exclusion criteria</italic></th></tr></thead><tbody><tr><td align="left">Multi-trauma patient<break/>ISS* &#x02265; 18<break/>Femur fracture<break/>Age 18-80 years<break/>Informed consent</td><td align="left">Congenital C1-inhibitor deficiency<break/>Use of immune suppressants<break/>Known hypersensitivity for blood<break/>Products<break/>Pregnancy<break/>Fixation of the femoral fracture with external fixation or osteosynthesis</td></tr></tbody></table><table-wrap-foot><p>*ISS = Injury Severity Score</p></table-wrap-foot></table-wrap></sec><sec><title>Randomization</title><p>Subjects are randomly allocated to either the C1-INH group (intervention-group) or the placebo-group just before the start of the surgical repair of the femur fracture, using an 1:1 allocation ratio. Randomization will be performed by the distributing pharmacy (UMCU, The Netherlands) with the use of Design version 2.0 (Systat Software Inc., Chicago, IL, USA). The C1-INH and placebo solutions are prepared in identical non-transparent infusion bags, ensuring the double-blind fashion of the study. Patients, treating surgeons, investigators and nursing personnel involved in the study will be unaware of the randomization, and therefore, the solution applied.</p></sec><sec><title>Study protocol</title><p>When trauma patients meet the inclusion criteria, a first blood sample is taken within 12 hours after trauma. This blood sample serves as a reference for the degree of inflammation immediately after injury. Because the first blood sample needs to be drawn within 12 hours after trauma, it is possible that the first sample is drawn without the necessary informed consent and will be analyzed directly. This delayed informed consent may be required because the inflammatory response after the initial trauma is visible in the blood within the first 12 hours after trauma. Of course, the informed consent is obtained as soon as possible if the patient or his/her legal representative is able to. If no consent is obtained, the analyzed blood and the data will be destroyed and the patients will not receive C1-INH or placebo, because the randomization will only take place after informed consent is obtained.</p><p>Patients receive femur fixation surgery according to the current protocol in the UMCU. Just after induction of anesthesia a second blood sample will be drawn and after this withdrawal the subject receives either C1-INH in a dose of 200 U/kg body weight (n = 35) or placebo (saline 0.9%, n = 35) intravenously. Two hours and six hours after the skin incision for the surgical procedure for femoral fixation the next blood samples are taken. The last samples are taken 24 and 48 hours and seven days after procedure of femoral fixation. An overview of the time frame of the study is shown in Figure <xref ref-type="fig" rid="F1">1</xref>.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Time frame</bold>.</p></caption><graphic xlink:href="1745-6215-12-223-1"/></fig></sec><sec><title>Outcome measurements</title><p>The primary outcome will be the change in serum IL-6 concentration before and after surgical repair of a femur fracture in trauma patients in the presence or absence of C1-INH. We have chosen IL-6 as our primary endpoint because IL-6 is one of the earliest released pro-inflammatory cytokines after trauma, which is detectable by multiplex assays. Several clinical studies have shown that IL-6 is a good marker for the severity of inflammatory response [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Because not all patients are operated at the exact same time after trauma we will use the &#x00394; IL-6 serum concentration (the difference in IL-6 level between t = 0, at the start of the operation, and t = 6, six hours after start of the operation) as our primary endpoint. This allows the detection of the difference between the systemic inflammation in patients treated with or without C1-INH.</p><p>Secondary biochemical outcomes include the production of various pro- and anti-inflammatory cytokines, cellular activation markers and complement. Various hematological variables and clinical chemistry measurements, such as haemoglobin, haematocrit, leukocyte count, platelet count, C-reactive protein and fibrinogen, are also determined. These values reflect the clinical condition of the patient and the severity of inflammation.</p><p>Secondary clinical outcomes include the effect of C1-INH on the presence or absence of ARDS or MODS and appearance of SIRS, sepsis or septic shock. To evaluate the presence of these clinical conditions the Systemic Response Syndrome (SIRS)-score [<xref ref-type="bibr" rid="B28">28</xref>] and the Sequential Organ Failure Assessment (SOFA)-score [<xref ref-type="bibr" rid="B29">29</xref>] will be calculated on a daily base during hospitalization of the study subjects. The duration of admission at the intensive care unit, duration of mechanical ventilation and total days of hospital admission are all recorded.</p></sec><sec><title>Sample size calculation</title><p>The sample size calculation is based on damping of the increase in serum IL-6 concentration by 30% in the C1-INH group, compared to the placebo group [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. With an expected standard deviation of 50% [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>] and a relevant decrease of IL-6 concentration of 30% [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>], 35 patients in each sample-group (C1-INH or placebo) are needed to find a statistically significant difference (power 80%, Type 1 error rate 0.05).</p></sec><sec><title>Statistical analysis</title><p>The primary endpoint, the &#x00394; IL-6, will be determined with the use of a Students' <italic>t-test</italic>. The occurrence of inflammatory complications, such as MODS and ARDS, will be examined with the use of a survival analysis, such as Kaplan Meier or Cox proportional Hazard [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>For comparisons, a <italic>t-test </italic>or Mann Whitney U-test will be used as appropriate.</p><p>Changes over time will be analyzed using repeated measurement analysis with time as within factor and treatment as between factor, using Analysis of Variance.</p><p>A <italic>p</italic>-value &#x0003c; 0.05 is considered statistically significant.</p><p>The data will be analyzed using software programs SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA).</p></sec><sec><title>Interim analysis</title><p>In this study there will be two analyses performed, one interim and the final analysis, using the O'Brien Fleming method [<xref ref-type="bibr" rid="B33">33</xref>]. The alpha used for the interim analysis will be 0.0054, and for the final analysis the alpha used will be 0.0492.</p><p>The interim analysis will be conducted by an independent Data Safety Monitoring Board (DSMB) after the inclusion of 35 succeeding patients, The DSMB is composed of three independent members, of which two clinicians and one statistician. After the interim analysis the DSMB is able to make recommendations. In case of clear benefit, harm or futility of the treatment, the DSMB might decide to end the study early.</p></sec></sec><sec><title>Discussion</title><p>This study represents a novel therapeutic approach for the attenuation of the inflammatory response in trauma patients undergoing surgical intervention. To our knowledge this is the first randomized, placebo-controlled trial examining the effect of the acute-phase protein C1-INH on the suppression of the dysfunctional inflammatory reaction in trauma patients during fixation of their femur fracture. Our research, focusing on the potential therapeutic effect of C1-INH, could have important impact on outcome of patients after a severe trauma.</p><p>C1-INH is proven to be effective as treatment for improving the outcome in a variety of inflammatory disease models [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref>], including SIRS induced by infusion of LPS [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>The dosage C1-INH of 200 U/kg bodyweight is distinct from earlier clinical studies. It is shown that C1-INH synthesis increases up to 2.5 times the normal rate during an acute phase response [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. Various states of severe inflammation, such as found during sepsis, burns and ARDS, give a rise in the consumption of C1-INH [<xref ref-type="bibr" rid="B36">36</xref>]. Nuijens and colleagues also showed a reduction in functional C1-INH in patients with sepsis complicated by shock or ARDS [<xref ref-type="bibr" rid="B37">37</xref>]. Caliezi et al claimed that this decrease in C1-INH levels, as result of the consumption, is probably due to a relative deficiency in functional C1-INH as result of enzymatic cleavage in inflamed or ischemic tissue [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>We also expect consumption of C1-INH in the severely injured trauma patients in our study and thus a relative deficiency in functional C1-INH. We hypothesize that this consumption is mainly due to (i) the trauma itself, (ii) the blood loss during trauma, (iii) the possible extra blood loss during operation, and (iv) the dilution of the blood compartment during resuscitation because of the use of e.g. saline infusion or packed cells (erythrocytes). To compensate this natural consumption of C1-INH in our patients, we will administer a dose of 200 U/kg bodyweight, approximately a dose of 14.000-16.000 U per patient. This dose is expected to increase the circulating C1-INH concentration at least as found under acute phase conditions [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>C1-INH is found to be well tolerated up to a dose of 19.000 units in patients suffering from acute myocardial infarction [<xref ref-type="bibr" rid="B38">38</xref>]. In the study of Str&#x000fc;ber et al a dose of 15.000 U, followed by 7.500 U and 5.000 U (total of 27.500 U) was administered and tolerated without any side effects [<xref ref-type="bibr" rid="B39">39</xref>].</p><p>It is anticipated that this study will take three years to complete. The study is expected to start in October of 2011 and will end after the last blood sample is drawn from the seventieth successful included patient.</p></sec><sec><title>Conclusion</title><p>To the best of our knowledge this study is the first randomized controlled trial designed to assess the use of C1-INH as a possible drug for attenuation of the inflammatory response in trauma patients after a second hit.</p><p>And, if our hypothesis is proved correct, it will result in increased functional outcome in trauma patients and reduced health care related costs.</p></sec><sec><title>Trial status</title><p>Start trial October 2011, no patients included yet.</p></sec><sec><title>Abbreviations</title><p>ARDS: Acute Respiratory Distress Syndrome; C1-INH: C1-esterase inhibitor; DCO: Damage Control Orthopedics; DSMB: Data Safety Monitoring Board; IL-6: Interleukin-6; ISS: Injury Severity Score; MODS: Multiple Organ Dysfunction Syndrome; SIRS: Systemic Inflammatory Response Syndrome; SOFA: Sequential Organ Failure Assessment; UMCU: University Medical Centre Utrecht</p></sec><sec><title>Competing interests</title><p>A. Koenderman and P. Strengers both work for Sanquin Blood Supply Foundation. The remaining authors declare to have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>MH, TV, LK and LPHL were involved in developing the original study design. MH, LK and LPHL developed the research protocols. AHLK and PFWS developed the design for the study medication. KJPW and LPHL are responsible for the clinical input. MH, LK and LPHL drafted the paper. All authors provided input into revisions of the paper and have approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>This trial is supported by a grant of Sanquin Blood Supply Foundation.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Hietbrink</surname><given-names>F</given-names></name><name><surname>Koenderman</surname><given-names>L</given-names></name><name><surname>Rijkers</surname><given-names>G</given-names></name><name><surname>Leenen</surname><given-names>L</given-names></name><article-title>Trauma: the role of the innate immune system</article-title><source>World J Emerg Surg</source><year>2006</year><volume>1</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/1749-7922-1-15</pub-id><pub-id pub-id-type="pmid">16759367</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Hietbrink</surname><given-names>F</given-names></name><name><surname>Oudijk</surname><given-names>EJ</given-names></name><name><surname>Braams</surname><given-names>R</given-names></name><name><surname>Koenderman</surname><given-names>L</given-names></name><name><surname>Leenen</surname><given-names>L</given-names></name><article-title>Aberrant regulation of polymorphonuclear phagocyte responsiveness in multitrauma patients</article-title><source>Shock</source><year>2006</year><volume>26</volume><issue>6</issue><fpage>558</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000233196.40989.78</pub-id><pub-id pub-id-type="pmid">17117129</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Pillay</surname><given-names>J</given-names></name><name><surname>Hietbrink</surname><given-names>F</given-names></name><name><surname>Koenderman</surname><given-names>L</given-names></name><name><surname>Leenen</surname><given-names>LP</given-names></name><article-title>The systemic inflammatory response induced by trauma is reflected by multiple phenotypes of blood neutrophils</article-title><source>Injury</source><year>2007</year><volume>38</volume><issue>12</issue><fpage>1365</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1016/j.injury.2007.09.016</pub-id><pub-id pub-id-type="pmid">18061190</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Ulvik</surname><given-names>A</given-names></name><name><surname>Kvale</surname><given-names>R</given-names></name><name><surname>Wentzel-Larsen</surname><given-names>T</given-names></name><name><surname>Flaatten</surname><given-names>H</given-names></name><article-title>Multiple organ failure after trauma affects even long-term survival and functional status</article-title><source>Crit Care</source><year>2007</year><volume>11</volume><issue>5</issue><fpage>R95.</fpage><pub-id pub-id-type="pmid">17784940</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Lenz</surname><given-names>A</given-names></name><name><surname>Franklin</surname><given-names>GA</given-names></name><name><surname>Cheadle</surname><given-names>WG</given-names></name><article-title>Systemic inflammation after trauma</article-title><source>Injury</source><year>2007</year><volume>38</volume><issue>12</issue><fpage>1336</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1016/j.injury.2007.10.003</pub-id><pub-id pub-id-type="pmid">18048040</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Cruickshank</surname><given-names>AM</given-names></name><name><surname>Fraser</surname><given-names>WD</given-names></name><name><surname>Burns</surname><given-names>HJ</given-names></name><name><surname>Van Damme</surname><given-names>J</given-names></name><name><surname>Shenkin</surname><given-names>A</given-names></name><article-title>Response of serum interleukin-6 in patients undergoing elective surgery of varying severity</article-title><source>Clin Sci (Lond)</source><year>1990</year><volume>79</volume><issue>2</issue><fpage>161</fpage><lpage>165</lpage></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Giannoudis</surname><given-names>PV</given-names></name><name><surname>Smith</surname><given-names>RM</given-names></name><name><surname>Bellamy</surname><given-names>MC</given-names></name><name><surname>Morrison</surname><given-names>JF</given-names></name><name><surname>Dickson</surname><given-names>RA</given-names></name><name><surname>Guillou</surname><given-names>PJ</given-names></name><article-title>Stimulation of the inflammatory system by reamed and unreamed nailing of femoral fractures. An analysis of the second hit</article-title><source>J Bone Joint Surg Br</source><year>1999</year><volume>81</volume><issue>2</issue><fpage>356</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1302/0301-620X.81B2.8988</pub-id><pub-id pub-id-type="pmid">10204951</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Gebhard</surname><given-names>F</given-names></name><name><surname>Pfetsch</surname><given-names>H</given-names></name><name><surname>Steinbach</surname><given-names>G</given-names></name><name><surname>Strecker</surname><given-names>W</given-names></name><name><surname>Kinzl</surname><given-names>L</given-names></name><name><surname>Bruckner</surname><given-names>UB</given-names></name><article-title>Is interleukin 6 an early marker of injury severity following major trauma in humans?</article-title><source>Arch Surg</source><year>2000</year><volume>135</volume><issue>3</issue><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1001/archsurg.135.3.291</pub-id><pub-id pub-id-type="pmid">10722030</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Giannoudis</surname><given-names>PV</given-names></name><name><surname>Harwood</surname><given-names>PJ</given-names></name><name><surname>Loughenbury</surname><given-names>P</given-names></name><name><surname>Van Griensven</surname><given-names>M</given-names></name><name><surname>Krettek</surname><given-names>C</given-names></name><name><surname>Pape</surname><given-names>HC</given-names></name><article-title>Correlation between IL-6 levels and the systemic inflammatory response score: can an IL-6 cutoff predict a SIRS state?</article-title><source>J Trauma</source><year>2008</year><volume>65</volume><issue>3</issue><fpage>646</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1097/TA.0b013e3181820d48</pub-id><pub-id pub-id-type="pmid">18784579</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Kobbe</surname><given-names>P</given-names></name><name><surname>Vodovotz</surname><given-names>Y</given-names></name><name><surname>Kaczorowski</surname><given-names>DJ</given-names></name><name><surname>Mollen</surname><given-names>KP</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name><name><surname>Pape</surname><given-names>HC</given-names></name><article-title>Patterns of cytokine release and evolution of remote organ dysfunction after bilateral femur fracture</article-title><source>Shock</source><year>2008</year><volume>30</volume><issue>1</issue><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1097/SHK.0b013e31815d190b</pub-id><pub-id pub-id-type="pmid">18562923</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Pape</surname><given-names>HC</given-names></name><name><surname>Griensven</surname><given-names>MV</given-names></name><name><surname>Hildebrand</surname><given-names>FF</given-names></name><name><surname>Tzioupis</surname><given-names>CT</given-names></name><name><surname>Sommer</surname><given-names>KL</given-names></name><name><surname>Krettek</surname><given-names>CC</given-names></name><name><surname>Giannoudis</surname><given-names>PV</given-names></name><article-title>Systemic inflammatory response after extremity or truncal fracture operations</article-title><source>J Trauma</source><year>2008</year><volume>65</volume><issue>6</issue><fpage>1379</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1097/TA.0b013e31818c8e8c</pub-id><pub-id pub-id-type="pmid">19077630</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Morley</surname><given-names>JR</given-names></name><name><surname>Smith</surname><given-names>RM</given-names></name><name><surname>Pape</surname><given-names>HC</given-names></name><name><surname>MacDonald</surname><given-names>DA</given-names></name><name><surname>Trejdosiewitz</surname><given-names>LK</given-names></name><name><surname>Giannoudis</surname><given-names>PV</given-names></name><article-title>Stimulation of the local femoral inflammatory response to fracture and intramedullary reaming: a preliminary study of the source of the second hit phenomenon</article-title><source>J Bone Joint Surg Br</source><year>2008</year><volume>90</volume><issue>3</issue><fpage>393</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1302/0301-620X.90B3.19688</pub-id><pub-id pub-id-type="pmid">18310768</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Pape</surname><given-names>HC</given-names></name><name><surname>Van Griensven</surname><given-names>M</given-names></name><name><surname>Rice</surname><given-names>J</given-names></name><name><surname>Gansslen</surname><given-names>A</given-names></name><name><surname>Hildebrand</surname><given-names>F</given-names></name><name><surname>Zech</surname><given-names>S</given-names></name><name><surname>Winny</surname><given-names>M</given-names></name><name><surname>Lichtinghagen</surname><given-names>R</given-names></name><name><surname>Krettek</surname><given-names>C</given-names></name><article-title>Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: determination of the clinical relevance of biochemical markers</article-title><source>J Trauma</source><year>2001</year><volume>50</volume><issue>6</issue><fpage>989</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1097/00005373-200106000-00004</pub-id><pub-id pub-id-type="pmid">11426112</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Tschoeke</surname><given-names>SK</given-names></name><name><surname>Hellmuth</surname><given-names>M</given-names></name><name><surname>Hostmann</surname><given-names>A</given-names></name><name><surname>Ertel</surname><given-names>W</given-names></name><name><surname>Oberholzer</surname><given-names>A</given-names></name><article-title>The early second hit in trauma management augments the proinflammatory immune response to multiple injuries</article-title><source>J Trauma</source><year>2007</year><volume>62</volume><issue>6</issue><fpage>1396</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1097/TA.0b013e318047b7f0</pub-id><pub-id pub-id-type="pmid">17563655</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Pape</surname><given-names>HC</given-names></name><name><surname>Giannoudis</surname><given-names>P</given-names></name><name><surname>Krettek</surname><given-names>C</given-names></name><article-title>The timing of fracture treatment in polytrauma patients: relevance of damage control orthopedic surgery</article-title><source>Am J Surg</source><year>2002</year><volume>183</volume><issue>6</issue><fpage>622</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1016/S0002-9610(02)00865-6</pub-id><pub-id pub-id-type="pmid">12095590</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Pape</surname><given-names>HC</given-names></name><article-title>Effects of changing strategies of fracture fixation on immunologic changes and systemic complications after multiple trauma: damage control orthopedic surgery</article-title><source>J Orthop Res</source><year>2008</year><volume>26</volume><issue>11</issue><fpage>1478</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1002/jor.20697</pub-id><pub-id pub-id-type="pmid">18524013</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Pape</surname><given-names>HC</given-names></name><name><surname>Grimme</surname><given-names>K</given-names></name><name><surname>Van Griensven</surname><given-names>M</given-names></name><name><surname>Sott</surname><given-names>AH</given-names></name><name><surname>Giannoudis</surname><given-names>P</given-names></name><name><surname>Morley</surname><given-names>J</given-names></name><name><surname>Roise</surname><given-names>O</given-names></name><name><surname>Ellingsen</surname><given-names>E</given-names></name><name><surname>Hildebrand</surname><given-names>F</given-names></name><name><surname>Wiebe</surname><given-names>B</given-names></name><name><surname>Krettek</surname><given-names>C</given-names></name><article-title>Impact of intramedullary instrumentation versus damage control for femoral fractures on immunoinflammatory parameters: prospective randomized analysis by the EPOFF Study Group</article-title><source>J Trauma</source><year>2003</year><volume>55</volume><issue>1</issue><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1097/01.TA.0000075787.69695.4E</pub-id><pub-id pub-id-type="pmid">12855874</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Morshed</surname><given-names>S</given-names></name><name><surname>Miclau</surname><given-names>T</given-names><suffix>III</suffix></name><name><surname>Bembom</surname><given-names>O</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Knudson</surname><given-names>MM</given-names></name><name><surname>Colford</surname><given-names>JM</given-names><suffix>Jr</suffix></name><article-title>Delayed internal fixation of femoral shaft fracture reduces mortality among patients with multisystem trauma</article-title><source>J Bone Joint Surg Am</source><year>2009</year><volume>91</volume><issue>1</issue><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.2106/JBJS.H.00338</pub-id><pub-id pub-id-type="pmid">19122073</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Pape</surname><given-names>HC</given-names></name><name><surname>Hildebrand</surname><given-names>F</given-names></name><name><surname>Pertschy</surname><given-names>S</given-names></name><name><surname>Zelle</surname><given-names>B</given-names></name><name><surname>Garapati</surname><given-names>R</given-names></name><name><surname>Grimme</surname><given-names>K</given-names></name><name><surname>Krettek</surname><given-names>C</given-names></name><name><surname>Reed</surname><given-names>RL</given-names></name><article-title>Changes in the management of femoral shaft fractures in polytrauma patients: from early total care to damage control orthopedic surgery</article-title><source>J Trauma</source><year>2002</year><volume>53</volume><issue>3</issue><fpage>452</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1097/00005373-200209000-00010</pub-id><pub-id pub-id-type="pmid">12352480</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Pape</surname><given-names>HC</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name><name><surname>Kobbe</surname><given-names>P</given-names></name><name><surname>Tarkin</surname><given-names>I</given-names></name><name><surname>Katsoulis</surname><given-names>S</given-names></name><name><surname>Peitzman</surname><given-names>A</given-names></name><article-title>Assessment of the clinical course with inflammatory parameters</article-title><source>Injury</source><year>2007</year><volume>38</volume><issue>12</issue><fpage>1358</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1016/j.injury.2007.09.026</pub-id><pub-id pub-id-type="pmid">18048038</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Dorresteijn</surname><given-names>MJ</given-names></name><name><surname>Visser</surname><given-names>T</given-names></name><name><surname>Cox</surname><given-names>LA</given-names></name><name><surname>Bouw</surname><given-names>MP</given-names></name><name><surname>Pillay</surname><given-names>J</given-names></name><name><surname>Koenderman</surname><given-names>AH</given-names></name><name><surname>Strengers</surname><given-names>PF</given-names></name><name><surname>Leenen</surname><given-names>LP</given-names></name><name><surname>van der Hoeven</surname><given-names>JG</given-names></name><name><surname>Koenderman</surname><given-names>L</given-names></name><name><surname>Pickkers</surname><given-names>P</given-names></name><article-title>C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia</article-title><source>Crit Care Med</source><year>2010</year><volume>38</volume><issue>11</issue><fpage>2139</fpage><lpage>2145</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181f17be4</pub-id><pub-id pub-id-type="pmid">20693886</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Caliezi</surname><given-names>C</given-names></name><name><surname>Wuillemin</surname><given-names>WA</given-names></name><name><surname>Zeerleder</surname><given-names>S</given-names></name><name><surname>Redondo</surname><given-names>M</given-names></name><name><surname>Eisele</surname><given-names>B</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><article-title>C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema</article-title><source>Pharmacol Rev</source><year>2000</year><volume>52</volume><issue>1</issue><fpage>91</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">10699156</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Zeerleder</surname><given-names>S</given-names></name><name><surname>Caliezi</surname><given-names>C</given-names></name><name><surname>van Mierlo</surname><given-names>G</given-names></name><name><surname>Eerenberg-Belmer</surname><given-names>A</given-names></name><name><surname>Sulzer</surname><given-names>I</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>Wuillemin</surname><given-names>WA</given-names></name><article-title>Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis</article-title><source>Clin Diagn Lab Immunol</source><year>2003</year><volume>10</volume><issue>4</issue><fpage>529</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">12853381</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Qin</surname><given-names>G</given-names></name><name><surname>Fernandes</surname><given-names>SM</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>AE</given-names><suffix>III</suffix></name><article-title>C1 inhibitor-mediated protection from sepsis</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><issue>6</issue><fpage>3966</fpage><lpage>3972</lpage><pub-id pub-id-type="pmid">17785834</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Bahador</surname><given-names>M</given-names></name><name><surname>Cross</surname><given-names>AS</given-names></name><article-title>From therapy to experimental model: a hundred years of endotoxin administration to human subjects</article-title><source>J Endotoxin Res</source><year>2007</year><volume>13</volume><issue>5</issue><fpage>251</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1177/0968051907085986</pub-id><pub-id pub-id-type="pmid">17986486</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="other"><article-title>The Declaration of Helsinki</article-title><comment>(September 20<sup>th </sup>2011) [<ext-link ext-link-type="uri" xlink:href="http://www.wma.net/en/30publications/10policies/b3/">http://www.wma.net/en/30publications/10policies/b3/</ext-link>]</comment></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="other"><article-title>The Good Clinical Practice Guidelines</article-title><comment>(September 20<sup>th </sup>2011) [<ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf</ext-link>]</comment></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Bone</surname><given-names>RC</given-names></name><name><surname>Balk</surname><given-names>RA</given-names></name><name><surname>Cerra</surname><given-names>FB</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Fein</surname><given-names>AM</given-names></name><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Schein</surname><given-names>RM</given-names></name><name><surname>Sibbald</surname><given-names>WJ</given-names></name><article-title>Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine</article-title><source>Chest</source><year>1992</year><volume>101</volume><issue>6</issue><fpage>1644</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.1378/chest.101.6.1644</pub-id><pub-id pub-id-type="pmid">1303622</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>de Mendonca</surname><given-names>A</given-names></name><name><surname>Cantraine</surname><given-names>F</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Takala</surname><given-names>J</given-names></name><name><surname>Suter</surname><given-names>PM</given-names></name><name><surname>Sprung</surname><given-names>CL</given-names></name><name><surname>Colardyn</surname><given-names>F</given-names></name><name><surname>Blecher</surname><given-names>S</given-names></name><article-title>Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine</article-title><source>Crit Care Med</source><year>1998</year><volume>26</volume><issue>11</issue><fpage>1793</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1097/00003246-199811000-00016</pub-id><pub-id pub-id-type="pmid">9824069</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Maier</surname><given-names>B</given-names></name><name><surname>Lefering</surname><given-names>R</given-names></name><name><surname>Lehnert</surname><given-names>M</given-names></name><name><surname>Laurer</surname><given-names>HL</given-names></name><name><surname>Steudel</surname><given-names>WI</given-names></name><name><surname>Neugebauer</surname><given-names>EA</given-names></name><name><surname>Marzi</surname><given-names>I</given-names></name><article-title>Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma</article-title><source>Shock</source><year>2007</year><volume>28</volume><issue>6</issue><fpage>668</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">18092384</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Stensballe</surname><given-names>J</given-names></name><name><surname>Christiansen</surname><given-names>M</given-names></name><name><surname>Tonnesen</surname><given-names>E</given-names></name><name><surname>Espersen</surname><given-names>K</given-names></name><name><surname>Lippert</surname><given-names>FK</given-names></name><name><surname>Rasmussen</surname><given-names>LS</given-names></name><article-title>The early IL-6 and IL-10 response in trauma is correlated with injury severity and mortality</article-title><source>Acta Anaesthesiol Scand</source><year>2009</year><volume>53</volume><issue>4</issue><fpage>515</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.2008.01801.x</pub-id><pub-id pub-id-type="pmid">19317866</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Bull</surname><given-names>K</given-names></name><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name><article-title>Survival analysis in observational studies</article-title><source>Stat Med</source><year>1997</year><volume>16</volume><issue>9</issue><fpage>1041</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19970515)16:9&#x0003c;1041::AID-SIM506&#x0003e;3.0.CO;2-F</pub-id><pub-id pub-id-type="pmid">9160498</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>O'Brien</surname><given-names>PC</given-names></name><name><surname>Fleming</surname><given-names>TR</given-names></name><article-title>A multiple testing procedure for clinical trials</article-title><source>Biometrics</source><year>1979</year><volume>35</volume><issue>3</issue><fpage>549</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.2307/2530245</pub-id><pub-id pub-id-type="pmid">497341</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Kirschfink</surname><given-names>M</given-names></name><name><surname>Nurnberger</surname><given-names>W</given-names></name><article-title>C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application</article-title><source>Mol Immunol</source><year>1999</year><volume>36</volume><issue>4-5</issue><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/S0161-5890(99)00048-6</pub-id><pub-id pub-id-type="pmid">10403475</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Wouters</surname><given-names>D</given-names></name><name><surname>Wagenaar-Bos</surname><given-names>I</given-names></name><name><surname>van Ham</surname><given-names>M</given-names></name><name><surname>Zeerleder</surname><given-names>S</given-names></name><article-title>C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor</article-title><source>Expert Opin Biol Ther</source><year>2008</year><volume>8</volume><issue>8</issue><fpage>1225</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1517/14712598.8.8.1225</pub-id><pub-id pub-id-type="pmid">18613773</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Kirschfink</surname><given-names>M</given-names></name><name><surname>Mollnes</surname><given-names>TE</given-names></name><article-title>C1-inhibitor: an anti-inflammatory reagent with therapeutic potential</article-title><source>Expert Opin Pharmacother</source><year>2001</year><volume>2</volume><issue>7</issue><fpage>1073</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1517/14656566.2.7.1073</pub-id><pub-id pub-id-type="pmid">11583058</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Nuijens</surname><given-names>JH</given-names></name><name><surname>Eerenberg-Belmer</surname><given-names>AJ</given-names></name><name><surname>Huijbregts</surname><given-names>CC</given-names></name><name><surname>Schreuder</surname><given-names>WO</given-names></name><name><surname>Felt-Bersma</surname><given-names>RJ</given-names></name><name><surname>Abbink</surname><given-names>JJ</given-names></name><name><surname>Thijs</surname><given-names>LG</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><article-title>Proteolytic inactivation of plasma C1- inhibitor in sepsis</article-title><source>J Clin Invest</source><year>1989</year><volume>84</volume><issue>2</issue><fpage>443</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1172/JCI114185</pub-id><pub-id pub-id-type="pmid">2668333</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>de Zwaan</surname><given-names>C</given-names></name><name><surname>Kleine</surname><given-names>AH</given-names></name><name><surname>Diris</surname><given-names>JH</given-names></name><name><surname>Glatz</surname><given-names>JF</given-names></name><name><surname>Wellens</surname><given-names>HJ</given-names></name><name><surname>Strengers</surname><given-names>PF</given-names></name><name><surname>Tissing</surname><given-names>M</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>van Dieijen-Visser</surname><given-names>MP</given-names></name><name><surname>Hermens</surname><given-names>WT</given-names></name><article-title>Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction</article-title><source>Eur Heart J</source><year>2002</year><volume>23</volume><issue>21</issue><fpage>1670</fpage><lpage>1677</lpage><pub-id pub-id-type="pmid">12398824</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Struber</surname><given-names>M</given-names></name><name><surname>Hagl</surname><given-names>C</given-names></name><name><surname>Hirt</surname><given-names>SW</given-names></name><name><surname>Cremer</surname><given-names>J</given-names></name><name><surname>Harringer</surname><given-names>W</given-names></name><name><surname>Haverich</surname><given-names>A</given-names></name><article-title>C1-esterase inhibitor in graft failure after lung transplantation</article-title><source>Intensive Care Med</source><year>1999</year><volume>25</volume><issue>11</issue><fpage>1315</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1007/s001340051065</pub-id><pub-id pub-id-type="pmid">10654221</pub-id></mixed-citation></ref></ref-list></back></article>